| Host |
Rabbit |
| Klon |
SP34 |
| Format |
Concentrate |
| Reaktivität |
CK, DG, MS |
| Methode |
P, FL |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide from C-terminus of human PAX-5 protein |
| Lokalisation |
Nucleus |
PAX-5
|
Zytomed Systems GmbH |
SP34 |
1 ml |
Concentrate |
RUO |
530-3344 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM26 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human full-length PAX-5 protein |
| Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZM26 |
1 ml |
Concentrate |
CE/IVD |
Z2354ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM26 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human full-length PAX-5 protein |
| Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZM26 |
7 ml |
Ready-to-use |
CE/IVD |
Z2354MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM26 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human full-length PAX-5 protein |
| Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZM26 |
0.5 ml |
Concentrate |
CE/IVD |
Z2354MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM26 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human full-length PAX-5 protein |
| Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZM26 |
0.1 ml |
Concentrate |
CE/IVD |
Z2354MT |
-
|
| Host |
Rabbit |
| Klon |
ZR268 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 235-382) of human PAX-5 protein |
| Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZR268 |
1 ml |
Concentrate |
CE/IVD |
Z2582RL |
-
|
| Host |
Rabbit |
| Klon |
ZR268 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 235-382) of human PAX-5 protein |
| Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZR268 |
7 ml |
Ready-to-use |
CE/IVD |
Z2582RP |
-
|
| Host |
Rabbit |
| Klon |
ZR268 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 235-382) of human PAX-5 protein |
| Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZR268 |
0.5 ml |
Concentrate |
CE/IVD |
Z2582RS |
-
|
| Host |
Rabbit |
| Klon |
ZR268 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 235-382) of human PAX-5 protein |
| Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZR268 |
0.1 ml |
Concentrate |
CE/IVD |
Z2582RT |
-
|
| Host |
Mouse |
| Klon |
BC12 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Kidney, renal cell carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
ag0306 |
| Lokalisation |
Nucleus |
PAX-8
|
Diagnostic Biosystems |
BC12 |
6 ml |
Ready-to-use |
CE/IVD |
PDM180 |
-
|
| Host |
Rabbit |
| Klon |
ZR1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ovarian serous carcinoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the C-terminus of Human PAX8 protein |
| Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZR1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2202RL |
-
|
| Host |
Rabbit |
| Klon |
ZR1 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ovarian serous carcinoma. |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the C-terminus of Human PAX8 protein |
| Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZR1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2202RP |
-
|
| Host |
Rabbit |
| Klon |
ZR1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ovarian serous carcinoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the C-terminus of Human PAX8 protein |
| Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZR1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2202RS |
-
|
| Host |
Rabbit |
| Klon |
ZR1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ovarian serous carcinoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the C-terminus of Human PAX8 protein |
| Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZR1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2202RT |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM28 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ovarian serous carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human PAX-8 protein |
| Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZM28 |
1 ml |
Concentrate |
CE/IVD |
Z2357ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM28 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ovarian serous carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human PAX-8 protein |
| Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZM28 |
7 ml |
Ready-to-use |
CE/IVD |
Z2357MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM28 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ovarian serous carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human PAX-8 protein |
| Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZM28 |
0.5 ml |
Concentrate |
CE/IVD |
Z2357MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM28 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ovarian serous carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human PAX-8 protein |
| Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZM28 |
0.1 ml |
Concentrate |
CE/IVD |
Z2357MT |
-
|
| Host |
Mouse |
| Klon |
PC10 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
CC1 |
| Positivkontrolle |
Breast cancer or prostate cancer |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant rat PCNA protein |
| Lokalisation |
Nucleus |
PCNA (PC10)
|
Biocare Medical |
PC10 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3255G |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
P, EL, WB |
| Positivkontrolle |
Breast |
| Verdünnung |
2.5 µg/mL |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding an internal region of human PCNA protein |
PCNA (Proliferating Cell Nuclear Antigen)
|
Zytomed Systems GmbH |
polyclonal |
50 µg |
Purified |
RUO |
616-0350 |
-
|
| Host |
Mouse |
| Klon |
PC10 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
1 ml |
Concentrate |
CE/IVD |
MOB083 |
-
|
| Host |
Mouse |
| Klon |
PC10 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
0.1 ml |
Concentrate |
CE/IVD |
MOB083-01 |
-
|
| Host |
Mouse |
| Klon |
PC10 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
0.5 ml |
Concentrate |
CE/IVD |
MOB083-05 |
-
|
| Host |
Mouse |
| Klon |
PC10 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
6 ml |
Ready-to-use |
CE/IVD |
PDM014 |
-
|
| Host |
Mouse |
| Klon |
PC10 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
25 ml |
Ready-to-use |
CE/IVD |
PDM014-25 |
-
|
| Host |
Mouse |
| Klon |
EH33 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG2a+IgG1 kappa |
| Verdünnung |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
| Lokalisation |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
1 ml |
Concentrate |
CE/IVD |
MOB573 |
-
|
| Host |
Mouse |
| Klon |
EH33 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG2a+IgG1 kappa |
| Verdünnung |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
| Lokalisation |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
0.1 ml |
Concentrate |
CE/IVD |
MOB573-01 |
-
|
| Host |
Mouse |
| Klon |
EH33 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG2a+IgG1 kappa |
| Verdünnung |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
| Lokalisation |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
0.5 ml |
Concentrate |
CE/IVD |
MOB573-05 |
-
|
| Host |
Mouse |
| Klon |
EH33 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG2a+IgG1 kappa |
| Verdünnung |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
| Lokalisation |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
6 ml |
Ready-to-use |
CE/IVD |
PDM573 |
-
|
| Host |
Mouse |
| Klon |
EH33 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG2a+IgG1 kappa |
| Verdünnung |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
| Lokalisation |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
25 ml |
Ready-to-use |
CE/IVD |
PDM573-25 |
-
|
| Host |
Mouse |
| Klon |
NAT105 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic |
PD-1 (CD279)
|
Biocare Medical |
NAT105 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3137AK |
-
|
| Host |
Mouse |
| Klon |
NAT105 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic |
PD-1 (CD279)
|
Biocare Medical |
NAT105 |
1 ml |
Concentrate |
CE/IVD |
ACI3137CK |
-
|
| Host |
Rabbit |
| Klon |
CAL20 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG1 |
| Lokalisation |
Cytoplasm and cell membrane |
PD-1 (CD279)
|
Biocare Medical |
CAL20 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3224A |
-
|
| Host |
Rabbit |
| Klon |
CAL20 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG1 |
| Lokalisation |
Cytoplasm and cell membrane |
PD-1 (CD279)
|
Biocare Medical |
CAL20 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3224B |
-
|
| Host |
Mouse |
| Klon |
NAT105 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm |
PD-1 (CD279)
|
Biocare Medical |
NAT105 |
6 ml |
Ready-to-use |
CE/IVD |
API3137AA |
-
|
| Host |
Rabbit |
| Klon |
EP239 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma, colon cancer |
| Verdünnung |
- |
| Isotyp |
IgG |
| Lokalisation |
Cytoplasm, cell membrane |
PD-1 (CD279)
|
Biocare Medical |
EP239 |
6 ml |
Ready-to-use |
CE/IVD |
API3162AA |
-
|
| Host |
Rabbit |
| Klon |
CAL20 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG1 |
| Lokalisation |
Cytoplasm and cell membrane |
PD-1 (CD279)
|
Biocare Medical |
CAL20 |
6 ml |
Ready-to-use |
CE/IVD |
API3224AA |
-
|
| Host |
Mouse |
| Klon |
ZM357 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph Node |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /k |
| Verdünnung |
Recombinant fragment (around aa1-200) of human PDCD1 protein |
| Lokalisation |
Cytoplasm, Cell Membrane |
PD-1 (PDCD1)
|
Zeta Corporation |
ZM357 |
1 ml |
Concentrate |
CE/IVD |
Z2424ML |
-
|
| Host |
Mouse |
| Klon |
ZM357 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph Node |
| Verdünnung |
- |
| Isotyp |
IgG1 /k |
| Verdünnung |
Recombinant fragment (around aa1-200) of human PDCD1 protein |
| Lokalisation |
Cytoplasm, Cell Membrane |
PD-1 (PDCD1)
|
Zeta Corporation |
ZM357 |
7 ml |
Concentrate |
CE/IVD |
Z2424MP |
-
|
| Host |
Mouse |
| Klon |
ZM357 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph Node |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /k |
| Verdünnung |
Recombinant fragment (around aa1-200) of human PDCD1 protein |
| Lokalisation |
Cytoplasm, Cell Membrane |
PD-1 (PDCD1)
|
Zeta Corporation |
ZM357 |
0.5 ml |
Concentrate |
CE/IVD |
Z2424MS |
-
|
| Host |
Mouse |
| Klon |
ZM357 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph Node |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /k |
| Verdünnung |
Recombinant fragment (around aa1-200) of human PDCD1 protein |
| Lokalisation |
Cytoplasm, Cell Membrane |
PD-1 (PDCD1)
|
Zeta Corporation |
ZM357 |
0.1 ml |
Concentrate |
CE/IVD |
Z2424MT |
-
|
| Host |
Rabbit |
| Klon |
ZR3 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta or lung adenocarcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
KLH-conjugated linear peptide corresponding tohuman PD-L1 |
| Lokalisation |
Cell membrane |
PD-L1
|
Zeta Corporation |
ZR3 |
1.0 ml |
Concentrate |
CE/IVD |
Z2002RL |
-
|
| Host |
Rabbit |
| Klon |
ZR3 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta or lung adenocarcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
KLH-conjugated linear peptide corresponding tohuman PD-L1 |
| Lokalisation |
Cell membrane |
PD-L1
|
Zeta Corporation |
ZR3 |
7 ml |
Ready-to-use |
CE/IVD |
Z2002RP |
-
|
| Host |
Rabbit |
| Klon |
ZR3 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta or lung adenocarcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
KLH-conjugated linear peptide corresponding tohuman PD-L1 |
| Lokalisation |
Cell membrane |
PD-L1
|
Zeta Corporation |
ZR3 |
0.5 ml |
Concentrate |
CE/IVD |
Z2002RS |
-
|
| Host |
Rabbit |
| Klon |
ZR3 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta or lung adenocarcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
KLH-conjugated linear peptide corresponding tohuman PD-L1 |
| Lokalisation |
Cell membrane |
PD-L1
|
Zeta Corporation |
ZR3 |
0.1 ml |
Concentrate |
CE/IVD |
Z2002RT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
IHC(P), WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Heart |
| Verdünnung |
2.5 µg/ml (~ 1:400) |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A peptide corresponding to a 17 amino acid sequence from near the centre of Human CD274. |
PD-L1 (CD274)
|
Zytomed Systems GmbH |
polyclonal |
100 µg (100 µl) |
Purified |
RUO |
603-2389 |
-
|
| Host |
Rabbit |
| Klon |
CAL10 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung adenocarcinoma, tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 |
| Lokalisation |
Cell membrane, cytoplasm |
PD-L1 (CD274)
|
Biocare Medical |
CAL10 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3171A |
-
|
| Host |
Rabbit |
| Klon |
CAL10 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung adenocarcinoma, tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 |
| Lokalisation |
Cell membrane, cytoplasm |
PD-L1 (CD274)
|
Biocare Medical |
CAL10 |
1 ml |
Concentrate |
CE/IVD |
ACI3171C |
-
|
| Host |
Rabbit |
| Klon |
CAL10 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
ER2 |
| Positivkontrolle |
Lung adenocarcinoma, tonsil |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Verdünnung |
Peptide corresponding to the region within human PD-L1 |
| Lokalisation |
Cell membrane, cytoplasm |
PD-L1 (CD274)
|
Biocare Medical |
CAL10 |
7 ml |
Ready-to-use |
RUO |
ALR3171G7 |
-
|
| Host |
Rabbit |
| Klon |
CAL10 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung adenocarcinoma, tonsil |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Lokalisation |
Cell membrane, cytoplasm |
PD-L1 (CD274)
|
Biocare Medical |
CAL10 |
6 ml |
Ready-to-use |
CE/IVD |
API3171AA |
-
|